{
  "id": "61fbc51ec9dfcb9c0900000f",
  "type": "list",
  "question": "Which drugs are in the Segluromet combination pill?",
  "ideal_answer": "Segluromet includes combinations of ertugliflozin and metformin. It has recently been approved by the US FDA as an adjunct to diet and exercise to improve glycaemic control in adults with T2DM.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30938372",
    "http://www.ncbi.nlm.nih.gov/pubmed/29476348",
    "http://www.ncbi.nlm.nih.gov/pubmed/30724637"
  ],
  "snippets": [
    {
      "text": "Ertugliflozin, a highly selective and reversible SGLT2 inhibitor, is the latest addition to the gliflozin class of SGLT2 inhibitors for the treatment of type 2 diabetes mellitus (T2DM). It was granted approval by the U.S. Food and Drug Administration (FDA) in December 2017 for treatment of T2DM as a monotherapy, and as part of two separate fixed-dose combination therapies with sitagliptin (Steglujan) and metformin (Segluromet).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30938372",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: Ertugliflozin and metformin hydrochloride (ertugliflozin/metformin, SEGLUROMET) is a recently approved fixed-dose combination tablet containing the sodium-glucose co-transporter 2 (SGLT-2) inhibitor ertugliflozin and metformin. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30724637",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ertugliflozin and fixed-dose combinations of ertugliflozin and metformin (Segluromet\u2122) and ertugliflozin and sitagliptin (Steglujan\u2122) have recently been approved by the US FDA as an adjunct to diet and exercise to improve glycaemic control in adults with T2DM. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29476348",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ertugliflozin and fixed-dose combinations of ertugliflozin and metformin (Segluromet\u2122) and ertugliflozin and sitagliptin (Steglujan\u2122) have recently been approved by the US FDA as an adjunct to diet and exercise to improve glycaemic control in adults with T2DM.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29476348",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "It was granted approval by the U.S. Food and Drug Administration (FDA) in December 2017 for treatment of T2DM as a monotherapy, and as part of two separate fixed-dose combination therapies with sitagliptin (Steglujan) and metformin (Segluromet).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30938372",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "poglycemia. Areas covered: Ertugliflozin and metformin hydrochloride (ertugliflozin/metformin, SEGLUROMET) is a recently approved fixed-dose combination tablet containing the sodium-glucose co-transporter 2 (SGLT-2) inhibitor ertugliflozin and met",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30724637",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "iflozin and fixed-dose combinations of ertugliflozin and metformin (Segluromet\u2122) and ertugliflozin and sitagliptin (Steglujan\u2122) have recently been approved by the US FDA as an adjunct to diet and exercise to improve glycaemic control in adults with T2DM. These prod",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29476348",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ranted approval by the U.S. Food and Drug Administration (FDA) in December 2017 for treatment of T2DM as a monotherapy, and as part of two separate fixed-dose combination therapies with sitagliptin (Steglujan) and metformin (Segluromet). Ertuglifloz",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30938372",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Food and Drug Administration (FDA) in December 2017 for treatment of T2DM as a monotherapy, and as part of two separate fixed-dose combination therapies with sitagliptin (Steglujan) and metformin (Segluromet)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30938372",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ertugliflozin and fixed-dose combinations of ertugliflozin and metformin (Segluromet\u2122) and ertugliflozin and sitagliptin (Steglujan\u2122) have recently been approved by the US FDA as an adjunct to diet and exercise to improve glycaemic control in adults with T2DM",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29476348",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "hypoglycemia. Areas covered: Ertugliflozin and metformin hydrochloride (ertugliflozin/metformin, SEGLUROMET) is a recently approved fixed-dose combination tablet containing the sodium-glucose co-transporter 2 (SGLT-2) inhibitor ertugliflozin ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30724637",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "ertugliflozin, metformin"
}